IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) and TransMedics Group (NASDAQ:TMDX – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.
Profitability
This table compares IDEXX Laboratories and TransMedics Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IDEXX Laboratories | 25.03% | 71.96% | 33.60% |
| TransMedics Group | 22.69% | 15.88% | 5.95% |
Analyst Recommendations
This is a breakdown of current recommendations for IDEXX Laboratories and TransMedics Group, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IDEXX Laboratories | 0 | 4 | 6 | 0 | 2.60 |
| TransMedics Group | 1 | 6 | 5 | 0 | 2.33 |
Risk and Volatility
IDEXX Laboratories has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.
Valuation and Earnings
This table compares IDEXX Laboratories and TransMedics Group”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IDEXX Laboratories | $4.30 billion | 9.55 | $1.06 billion | $14.22 | 36.67 |
| TransMedics Group | $605.49 million | 5.03 | $190.29 million | $3.89 | 22.64 |
IDEXX Laboratories has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
IDEXX Laboratories beats TransMedics Group on 11 of the 14 factors compared between the two stocks.
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
About TransMedics Group
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
